Next Article in Journal
Optimized Chitosan/Anion Polyelectrolyte Complex Based Inserts for Vaginal Delivery of Fluconazole: In Vitro/In Vivo Evaluation
Previous Article in Journal
Polyamidoamine Nanoparticles for the Oral Administration of Antimalarial Drugs
Previous Article in Special Issue
Targeted Theranostic Nanoparticles for Brain Tumor Treatment
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(4), 226; https://doi.org/10.3390/pharmaceutics10040226

Co-Administered Polymeric Nano-Antidotes for Improved Photo-Triggered Response in Glioblastoma

1
Biomedical Engineering and Biotechnology Program, University of Massachusetts Lowell, 1 University Ave, Lowell, MA 01854, USA
2
Department of Chemical Engineering, University of Massachusetts Lowell, 1 University Ave, Lowell, MA 01854, USA
*
Author to whom correspondence should be addressed.
Received: 15 October 2018 / Revised: 3 November 2018 / Accepted: 7 November 2018 / Published: 10 November 2018
(This article belongs to the Special Issue Nanotheranostics and Cancer: Where Are We Now?)
Full-Text   |   PDF [3186 KB, uploaded 10 November 2018]   |  

Abstract

Polymer-based nanoparticles (NPs) are useful vehicles in treating glioblastoma because of their favorable characteristics such as small size and ability to cross the blood–brain barrier, as well as reduced immunogenicity and side effects. The use of a photosensitizer drug such as Verteporfin (BPD), in combination with a pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), Cediranib (CED), encapsulated in NPs will provide the medical field with new research on the possible ways to treat glioblastoma. Concomitant administration of BPD and CED NPs have the potential to induce dual photocytotoxic and cytostatic effects in U87 MG cells by (1) remotely triggering BPD through photodynamic therapy by irradiating laser at 690 nm and subsequent production of reactive oxygen species and (2) inhibiting cell proliferation by VEGFR interference and growth factor signaling mechanisms which may allow for longer progression free survival in patients and fewer systemic side effects. The specific aims of this research were to synthesize, characterize and assess cell viability and drug interactions for polyethylene-glycolated (PEGylated) polymeric based CED and BPD NPs which were less than 100 nm in size for enhanced permeation and retention effects. Synergistic effects were found using the co-administered therapies compared to the individual drugs. The major goal of this research was to investigate a new combination of photodynamic-chemotherapy drugs in nano-formulation for increased efficacy in glioblastoma treatment at reduced concentrations of therapeutics for enhanced drug delivery in vitro. View Full-Text
Keywords: drug delivery; cancer; polymer; nanomedicine; angiogenesis; blood–brain barrier drug delivery; cancer; polymer; nanomedicine; angiogenesis; blood–brain barrier
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Kydd, J.; Jadia, R.; Rai, P. Co-Administered Polymeric Nano-Antidotes for Improved Photo-Triggered Response in Glioblastoma. Pharmaceutics 2018, 10, 226.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top